Back to discover

Protein / target

Fibroblast growth factor receptor 1

Encoded byFGFR1P11362Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
12
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Fibroblast growth factor receptor

Primary biology

FGFR growth-factor signalling

Strongest disease association

Hypogonadotropic hypogonadism 2 with or without anosmia

Via encoding gene FGFR1 · Genetic evidence · score 0.98

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration.

View complete UniProt function annotation

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation

Subcellular location

Cell membraneNucleusCytoplasm, cytosolCytoplasmic vesicle
Domains and Gene Ontology detail (56)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Protein kinase

Gene Ontology

  • Ccytoplasmic vesicle
  • Ccytosol
  • Cextracellular region
  • Cglutamatergic synapse
  • Cmembrane
  • Cnucleus
  • Cplasma membrane
  • Cpostsynapse
  • Creceptor complex
  • FATP binding
  • Ffibroblast growth factor binding
  • Ffibroblast growth factor receptor activity

822 aa · 92 kDa · 21 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Growth-factor signallingUniProt · GOCell proliferation & survivalGO · ReactomeSynaptic signallingGOCell migrationGOOncogenic signallingReactomeKinase signallingUniProt · GO
View supporting evidence

Growth-factor signalling

  • ·Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth facto…
  • ·fibroblast growth factor binding
  • ·fibroblast growth factor receptor activity
  • ·cellular response to fibroblast growth factor stimulus

Cell proliferation & survival

  • ·positive regulation of cell population proliferation
  • ·PIP3 activates AKT signaling
  • ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Synaptic signalling

  • ·glutamatergic synapse
  • ·postsynapse
  • ·regulation of postsynaptic density assembly

Cell migration

  • ·cell migration
  • ·positive regulation of blood vessel endothelial cell migration
  • ·positive regulation of endothelial cell chemotaxis

Oncogenic signalling

  • ·Constitutive Signaling by Aberrant PI3K in Cancer

Kinase signalling

  • ·Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth facto…
  • ·protein tyrosine kinase activity
  • ·positive regulation of MAP kinase activity
  • ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
View underlying pathways (22)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

FGF18FRS2FGF23FGF3FGF6FGF20FGF1KLFGF16FGF10FGFR1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

4 medicines · 5 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Cholangiocarcinoma2 medicines
Carcinoma, Transitional Cell1 medicine
Colorectal Neoplasms1 medicine
Urinary Bladder Neoplasms1 medicine
Broader indication categories (1)

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

12 medicines meet Open Targets' target-level approved-medicine definition; the 4 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

4

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

pemigatinib
Narrow target profileApprovedInhibitor

Fibroblast growth factor receptor 1 inhibitor

Indicated for Cholangiocarcinoma, Neoplasms

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

regorafenib
ApprovedInhibitor

Fibroblast growth factor receptor 1 inhibitor

Indicated for Colorectal Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 18 recorded protein targets — broad pharmacology

erdafitinib
ApprovedInhibitor

Fibroblast growth factor receptor inhibitor

Indicated for Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasms

Acts on a complex — shared with FGFR3, FGFR4, FGFR2 · 1 of 4 recorded protein targets

futibatinib
ApprovedInhibitor

Fibroblast growth factor receptor inhibitor

Indicated for Cholangiocarcinoma, Neoplasms

Acts on a complex — shared with FGFR3, FGFR4, FGFR2 · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FGFR1

Gene-level evidence surfaced through the gene FGFR1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypogonadotropic hypogonadism 2 with or without anosmia
0.98Well supported

Genetic evidence dominant · Open Targets 0.85

Encephalocraniocutaneous lipomatosis
0.93Well supported

Genetic evidence dominant · Open Targets 0.76

Hartsfield-Bixler-Demyer syndrome
0.93Well supported

Genetic evidence dominant · Open Targets 0.83

Pfeiffer syndrome
0.90Well supported

Genetic evidence dominant · Open Targets 0.79

Osteoglophonic dysplasia
0.89Well supported

Genetic evidence dominant · Open Targets 0.77

View evidence synthesis (5)
Hypogonadotropic hypogonadism 2 with or without anosmiaWell supported
0.98
agreement 0.861.00
Genetic88%Animal model12%Literature1%Genetic literaturedup

Open Targets aggregate 0.85 · 3 independent evidence families · 1 not counted as duplicate

Encephalocraniocutaneous lipomatosisWell supported
0.93
agreement 0.831.00
Genetic61%Somatic mutation29%Animal model7%Literature2%Genetic literaturedup

Open Targets aggregate 0.76 · 4 independent evidence families · 1 not counted as duplicate

Hartsfield-Bixler-Demyer syndromeWell supported
0.93
agreement 0.811.00
Genetic79%Animal model16%Literature5%Genetic literaturedup

Open Targets aggregate 0.83 · 3 independent evidence families · 1 not counted as duplicate

Pfeiffer syndromeWell supported
0.90
agreement 0.781.00
Genetic79%Animal model19%Literature2%Genetic literaturedup

Open Targets aggregate 0.79 · 3 independent evidence families · 1 not counted as duplicate

Osteoglophonic dysplasiaWell supported
0.89
agreement 0.771.00
Genetic78%Animal model21%Literature2%Genetic literaturedup

Open Targets aggregate 0.77 · 3 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypogonadotropic hypogonadism 2 with or without anosmia0.85
Hartsfield-Bixler-Demyer syndrome0.83
Pfeiffer syndrome0.79
Osteoglophonic dysplasia0.77
Hypogonadism0.77
Encephalocraniocutaneous lipomatosis0.76
Neoplasms0.75
Kallmann syndrome0.74
Jackson-Weiss syndrome0.72
Trigonocephaly 10.72

Drug development

26 compounds recorded · 12 approved · 14 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 4 drugs that target this protein in Forefront's canonical graph (4 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
TG100-801Phase 2
E-7090Approval
NINTEDANIB ESYLATEApproval
PAZOPANIBApproval
FGFR INHIBITOR DEBIO 1347Phase 2
INFIGRATINIBApproval
FEXAGRATINIBPhase 2
SURUFATINIBApproval
ENMD-981693Phase 2
LY-2874455Phase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (14)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

anaemiaBrennan et al. (2024)hypophosphataemiaBrennan et al. (2024)decreased platelet countBrennan et al. (2024)weight lossBrennan et al. (2024)keratitisBrennan et al. (2024)decreased food intakeBrennan et al. (2024)HyperphosphataemiaBrennan et al. (2024)AST elevationsBrennan et al. (2024)dry eyeBrennan et al. (2024)reduced sweet tasteBrennan et al. (2024)dermatologic toxicityClinPGxregulation of catalytic activityToxCast

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

11

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2024-08-22

    Approval: Balversa (EMA)

    ema · regulatory · ema · via erdafitinib

  2. New publication2024-06-04
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 69 citations · Europe PMC · via regorafenib

  3. Regulatory approval2023-07-04

    Approval: Lytgobi (EMA)

    ema · regulatory · ema · via futibatinib

  4. New publication2023-01-01
    Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic Cholangiocarcinoma.

    The New England journal of medicine · 2023 · 420 citations · Europe PMC · via futibatinib

  5. Regulatory approval2021-03-26

    Approval: Pemazyre (EMA)

    ema · regulatory · ema · via pemigatinib

  6. New publication2020-08-11
    Targeted therapy for hepatocellular carcinoma.

    Signal transduction and targeted therapy · 2020 · 565 citations · Europe PMC · via regorafenib

  7. New publication2019-11-04
    Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.

    Journal of experimental & clinical cancer research : CR · 2019 · 162 citations · Europe PMC · via regorafenib

  8. New publication2019-07-01
    Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

    The New England journal of medicine · 2019 · 1,006 citations · Europe PMC · via erdafitinib

  9. New publication2019-04-23
    Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · 199 citations · Europe PMC · via regorafenib

  10. New publication2016-12-06
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet (London, England) · 2017 · 2,767 citations · Europe PMC · via regorafenib

  11. Regulatory approval2013-08-26

    Approval: Stivarga (EMA)

    ema · regulatory · ema · via regorafenib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.